Jan A. Burger

2.2k total citations · 1 hit paper
26 papers, 1.6k citations indexed

About

Jan A. Burger is a scholar working on Genetics, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jan A. Burger has authored 26 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 10 papers in Hematology and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jan A. Burger's work include Chronic Lymphocytic Leukemia Research (20 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Jan A. Burger is often cited by papers focused on Chronic Lymphocytic Leukemia Research (20 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). Jan A. Burger collaborates with scholars based in United States, Italy and Canada. Jan A. Burger's co-authors include Nathan J. Zvaifler, Thomas J. Kipps, Nobuhiro Tsukada, Gill Adams, Christopher Edwards, Ravinder N. Maini, Michael J. Keating, Gary S. Firestein, Wan Zhang and Celia Garcı́a-Prieto and has published in prestigious journals such as Journal of Clinical Investigation, Blood and Nature Cell Biology.

In The Last Decade

Jan A. Burger

25 papers receiving 1.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mesenchymal precursor cells in the blood of normal individuals

2000 561 citations Nathan J. Zvaifler, Gill Adams et al. Arthritis Research & Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan A. Burger United States	10	956	478	409	305	278	26	1.6k
Basile Stamatopoulos Belgium	23	764 0.8×	779 1.6×	380 0.9×	229 0.8×	284 1.0×	50	1.6k
María Dolores Tabernero Spain	28	824 0.9×	712 1.5×	256 0.6×	167 0.5×	373 1.3×	68	2.2k
Enrique J. Andreu Spain	26	1.1k 1.1×	896 1.9×	276 0.7×	162 0.5×	398 1.4×	46	2.4k
Robert Pytlík Czechia	23	483 0.5×	499 1.0×	267 0.7×	457 1.5×	473 1.7×	91	1.5k
Christoph Walz Germany	25	679 0.7×	650 1.4×	466 1.1×	186 0.6×	375 1.3×	70	2.1k
Jianyu Weng China	19	681 0.7×	836 1.7×	519 1.3×	85 0.3×	507 1.8×	84	2.1k
David J. J. de Gorter Netherlands	18	304 0.3×	756 1.6×	299 0.7×	239 0.8×	311 1.1×	24	1.5k
Xin Du China	20	539 0.6×	849 1.8×	449 1.1×	94 0.3×	512 1.8×	74	1.8k
Daniele Reverberi Italy	18	664 0.7×	869 1.8×	314 0.8×	140 0.5×	198 0.7×	46	1.6k
Andréï Tchirkov France	22	479 0.5×	702 1.5×	151 0.4×	174 0.6×	389 1.4×	88	1.7k

Countries citing papers authored by Jan A. Burger

Since Specialization

Citations

This map shows the geographic impact of Jan A. Burger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan A. Burger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan A. Burger more than expected).

Fields of papers citing papers by Jan A. Burger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan A. Burger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan A. Burger. The network helps show where Jan A. Burger may publish in the future.

Co-authorship network of co-authors of Jan A. Burger

This figure shows the co-authorship network connecting the top 25 collaborators of Jan A. Burger. A scholar is included among the top collaborators of Jan A. Burger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan A. Burger. Jan A. Burger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burger, Jan A., Neil E. Kay, John N. Allan, et al.. (2024). Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up. Blood. 144(Supplement 1). 4615–4615.

Ghia, Paolo, Carolyn Owen, John N. Allan, et al.. (2024). First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis. HemaSphere. 8(5). e74–e74. 7 indexed citations

Senapati, Jayastu, Nicholas J. Short, Yesid Alvarado, et al.. (2022). A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood. 140(Supplement 1). 3253–3255. 5 indexed citations

Kantarjian, Hagop M., Elias Jabbour, Gautam Borthakur, et al.. (2022). Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL). Blood. 140(Supplement 1). 11671–11673. 3 indexed citations

Haddad, Fadi, Koji Sasaki, Ghayas C. Issa, et al.. (2022). Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia. Blood. 140(Supplement 1). 1493–1494. 5 indexed citations

Assi, Rita, Hagop M. Kantarjian, Nicholas J. Short, et al.. (2017). Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia. Clinical Lymphoma Myeloma & Leukemia. 17. S265–S265. 4 indexed citations

Sanford, David, William G. Wierda, Jan A. Burger, Michael J. Keating, & Susan O’Brien. (2015). Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clinical Lymphoma Myeloma & Leukemia. 15(7). 385–391. 19 indexed citations

Brown, Jennifer R., Jacqueline C. Barrientos, Paul M. Barr, et al.. (2015). The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 125(19). 2915–2922. 91 indexed citations

Wodarz, Dominik, Naveen Garg, Natalia L. Komarova, et al.. (2014). Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 123(26). 4132–4135. 78 indexed citations

10.

Ferrajoli, Alessandra, Jan A. Burger, Nitin Jain, et al.. (2014). An Observational Study of the Occurrence of Atrial Fibrillation and Hypertension in Patients Treated with Ibrutinib. Blood. 124(21). 5657–5657. 9 indexed citations

11.

Baljević, Muhamed, Hagop M. Kantarjian, Deborah A. Thomas, et al.. (2013). Incidence and Outcome In Adults With Acute Lymphoblastic Leukemia With Primary Central Nervous System Involvement. Blood. 122(21). 2639–2639. 1 indexed citations

12.

Wodarz, Dominik, Naveen Garg, Natalia L. Komarova, et al.. (2013). Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib. Blood. 122(21). 4166–4166. 1 indexed citations

13.

Zhang, Wan, Dunyaporn Trachootham, Jinyun Liu, et al.. (2012). Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nature Cell Biology. 14(3). 276–286. 280 indexed citations

14.

Burger, Jan A.. (2012). Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Current Opinion in Oncology. 24(6). 643–649. 55 indexed citations

15.

Daver, Naval, Hagop M. Kantarjian, Guillermo Garcia‐Manero, et al.. (2012). Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood. 120(21). 3619–3619. 4 indexed citations

16.

Jain, Preetesh, Long Trinh, Ohad Benjamini, et al.. (2012). Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.. Blood. 120(21). 2890–2890. 1 indexed citations

17.

Ravandi, Farhad, Deborah Thomas, Hagop Kantarjian, et al.. (2008). Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood. 112(11). 2921–2921. 5 indexed citations

18.

Burger, Jan A.. (2007). Fledgling prognostic markers in CLL. Blood. 110(12). 3820–3821. 1 indexed citations

19.

Burger, Jan A., Nathan J. Zvaifler, Nobuhiro Tsukada, Gary S. Firestein, & Thomas J. Kipps. (2001). Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell–derived factor-1– and CD106 (VCAM-1)–dependent mechanism. Journal of Clinical Investigation. 107(3). 305–315. 153 indexed citations

20.

Zvaifler, Nathan J., et al.. (2000). Mesenchymal precursor cells in the blood of normal individuals. Arthritis Research & Therapy. 2(6). 477–88. 561 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact